Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;12(1):30-37.
doi: 10.1002/cam4.4946. Epub 2022 Jun 20.

Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark

Vera Ehrenstein  1 , Katrine Eriksen  1 , Aliki Taylor  2 , Leslie Servidio  3 , Erik Jakobsen  4
Affiliations

Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark

Vera Ehrenstein et al. Cancer Med. 2023 Jan.

Abstract

Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer diagnoses, and approximately 35% of patients with NSCLC are diagnosed at an early stage (I-IIIA). This study aimed to describe epidermal growth factor receptor (EGFR) testing, patient characteristics, and overall survival (OS) among patients with early-stage NSCLC in Denmark. Patients with early-stage NSCLC registered in the Danish Lung Cancer Registry in 2013-2018 were followed through 2019. We described EGFR testing, descriptively summarised patient characteristics, and calculated OS by EGFR testing and mutation status. The association between EGFR mutation (EGFRm) and all-cause mortality was estimated using Cox proportional-hazards regression, in subgroups defined by stage at diagnosis, age at diagnosis, comorbidity, and receipt of surgery. In 2013-2018, 21,282 patients with NSCLC were registered in the Danish Lung Cancer Registry, of whom 8758 were diagnosed at an early stage. Of those, 4071 (46%) were tested for EGFRm at diagnosis. Median OS was 5.7 years among patients with EGFRm-positive status (n = 361) and 4.4 years among patients with EGFRm-negative status (n = 3710). EGFRm-positive status was associated with lower all-cause mortality in all subgroups. This study contributes to population-based evidence on the epidemiology of early-stage NSCLC treated in routine clinical practice.

Keywords: cohort study; epidermal growth factor receptor mutation; non-small cell lung cancer; overall survival.

PubMed Disclaimer

Conflict of interest statement

Vera Ehrenstein and Katrine Eriksen are salaried employees of Aarhus University or Aarhus University Hospital. Aliki Taylor and Leslie Servidio are or were at the time of the study conduct salaried employees of AstraZeneca. Erik Jakobsen is a salaried employee of Odense University Hospital.

Figures

FIGURE 1
FIGURE 1
Overall survival and EGFR mutation status among patients with early‐stage (I–IIIA) NSCLC, overall and by stage at diagnosis. *The figure shows OS by EGFR mutation status overall (Panel A), stage IA (Panel B), stage IB (Panel C), stage IIA (Panel D), stage IIB (Panel E), and stage IIIA (Panel F); EGFR, epidermal growth factor receptor; NSCLC, non‐small cell lung cancer; OS, overall survival.
See this image and copyright information in PMC

References

    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non‐small cell lung cancer. Nature. 2018;553:446‐454. - PubMed
    1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non‐small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584‐594. - PMC - PubMed
    1. Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2017;12(7):1109‐1121. - PubMed
    1. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975–2015. National Cancer Institute. 2017. Available from: https://seer.cancer.gov/csr/1975_2015/.
    1. Pignon J‐P, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552‐3559. - PubMed

Publication types

MeSH terms